PortalPublikationenCytotoxic tumour-infiltrating T lymphocytes influence outcom...

Cytotoxic tumour-infiltrating T lymphocytes influence outcome in resected pancreatic ductal adenocarcinoma

Standard

Cytotoxic tumour-infiltrating T lymphocytes influence outcome in resected pancreatic ductal adenocarcinoma. / Lohneis, Philipp; Sinn, Marianne; Bischoff, Sven; Jühling, Anja; Pelzer, Uwe; Wislocka, Lilianna; Bahra, Marcus; Sinn, Bruno V; Denkert, Carsten; Oettle, Helmut; Bläker, Hendrik; Riess, Hanno; Jöhrens, Korinna; Striefler, Jana K.

in: EUR J CANCER, Jahrgang 83, 09.2017, S. 290-301.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Lohneis, P, Sinn, M, Bischoff, S, Jühling, A, Pelzer, U, Wislocka, L, Bahra, M, Sinn, BV, Denkert, C, Oettle, H, Bläker, H, Riess, H, Jöhrens, K & Striefler, JK 2017, 'Cytotoxic tumour-infiltrating T lymphocytes influence outcome in resected pancreatic ductal adenocarcinoma', EUR J CANCER, Jg. 83, S. 290-301. https://doi.org/10.1016/j.ejca.2017.06.016

APA

Lohneis, P., Sinn, M., Bischoff, S., Jühling, A., Pelzer, U., Wislocka, L., Bahra, M., Sinn, B. V., Denkert, C., Oettle, H., Bläker, H., Riess, H., Jöhrens, K., & Striefler, J. K. (2017). Cytotoxic tumour-infiltrating T lymphocytes influence outcome in resected pancreatic ductal adenocarcinoma. EUR J CANCER, 83, 290-301. https://doi.org/10.1016/j.ejca.2017.06.016

Vancouver

Lohneis P, Sinn M, Bischoff S, Jühling A, Pelzer U, Wislocka L et al. Cytotoxic tumour-infiltrating T lymphocytes influence outcome in resected pancreatic ductal adenocarcinoma. EUR J CANCER. 2017 Sep;83:290-301. https://doi.org/10.1016/j.ejca.2017.06.016

Bibtex

@article{4fa504b602d1432ba183ddb27ad5335c,
title = "Cytotoxic tumour-infiltrating T lymphocytes influence outcome in resected pancreatic ductal adenocarcinoma",
abstract = "BACKGROUND: We studied the prognostic effect of CD3-, CD8- and CD103-positive T lymphocytes in a cohort of 165 patients with resected pancreatic ductal adenocarcinomas (PDACs) of the treatment group (adjuvant gemcitabine) and the untreated control group of the CONKO-001 study.METHODS: Immunohistochemical stainings on tissue microarrays (TMAs) against CD3, CD8 and CD103 were performed according to standard procedures.RESULTS: A high number of CD8-positive lymphocytes were significantly and independently associated with longer disease-free survival (DFS) and overall survival (OS) in the overall study population. Median DFS/OS were 7.4/18.1 months for patients with a low number of CD8-positive intratumoural lymphocytes (≤42 per 1 mm tissue core) and 12.7/25.2 months for patients with high numbers (>42 per 1-mm tissue core; p = 0.008/0.020; HR 0.62/0.65). The ratio of intraepithelial to total CD103-positive lymphocytes, but not total numbers of CD103-positive lymphocytes or CD103-positive intraepithelial lymphocytes, was associated with significantly improved DFS and OS in the overall study population (p = 0.022/0.009). Median DFS/OS was 5.9/15.7 for patients with a ratio of intraepithelial to total CD103-positive intratumoural lymphocytes higher than 0.3 and 11.6/24.7 for patients with a lower ratio.CONCLUSION: T-lymphocyte subpopulations might be prognostic in resectable PDAC but need standardization and verification by further studies.",
keywords = "Adult, Aged, Aged, 80 and over, Antimetabolites, Antineoplastic/therapeutic use, CD3 Complex/metabolism, CD8-Positive T-Lymphocytes/immunology, Carcinoma, Pancreatic Ductal/immunology, Deoxycytidine/analogs & derivatives, Disease-Free Survival, Female, Humans, Integrin beta4/analysis, Lymphocytes, Tumor-Infiltrating/immunology, Male, Middle Aged, Pancreatic Neoplasms/immunology, Prognosis, T-Lymphocytes, Cytotoxic/immunology",
author = "Philipp Lohneis and Marianne Sinn and Sven Bischoff and Anja J{\"u}hling and Uwe Pelzer and Lilianna Wislocka and Marcus Bahra and Sinn, {Bruno V} and Carsten Denkert and Helmut Oettle and Hendrik Bl{\"a}ker and Hanno Riess and Korinna J{\"o}hrens and Striefler, {Jana K}",
note = "Copyright {\textcopyright} 2017 Elsevier Ltd. All rights reserved.",
year = "2017",
month = sep,
doi = "10.1016/j.ejca.2017.06.016",
language = "English",
volume = "83",
pages = "290--301",
journal = "EUR J CANCER",
issn = "0959-8049",
publisher = "Elsevier Limited",

}

RIS

TY - JOUR

T1 - Cytotoxic tumour-infiltrating T lymphocytes influence outcome in resected pancreatic ductal adenocarcinoma

AU - Lohneis, Philipp

AU - Sinn, Marianne

AU - Bischoff, Sven

AU - Jühling, Anja

AU - Pelzer, Uwe

AU - Wislocka, Lilianna

AU - Bahra, Marcus

AU - Sinn, Bruno V

AU - Denkert, Carsten

AU - Oettle, Helmut

AU - Bläker, Hendrik

AU - Riess, Hanno

AU - Jöhrens, Korinna

AU - Striefler, Jana K

N1 - Copyright © 2017 Elsevier Ltd. All rights reserved.

PY - 2017/9

Y1 - 2017/9

N2 - BACKGROUND: We studied the prognostic effect of CD3-, CD8- and CD103-positive T lymphocytes in a cohort of 165 patients with resected pancreatic ductal adenocarcinomas (PDACs) of the treatment group (adjuvant gemcitabine) and the untreated control group of the CONKO-001 study.METHODS: Immunohistochemical stainings on tissue microarrays (TMAs) against CD3, CD8 and CD103 were performed according to standard procedures.RESULTS: A high number of CD8-positive lymphocytes were significantly and independently associated with longer disease-free survival (DFS) and overall survival (OS) in the overall study population. Median DFS/OS were 7.4/18.1 months for patients with a low number of CD8-positive intratumoural lymphocytes (≤42 per 1 mm tissue core) and 12.7/25.2 months for patients with high numbers (>42 per 1-mm tissue core; p = 0.008/0.020; HR 0.62/0.65). The ratio of intraepithelial to total CD103-positive lymphocytes, but not total numbers of CD103-positive lymphocytes or CD103-positive intraepithelial lymphocytes, was associated with significantly improved DFS and OS in the overall study population (p = 0.022/0.009). Median DFS/OS was 5.9/15.7 for patients with a ratio of intraepithelial to total CD103-positive intratumoural lymphocytes higher than 0.3 and 11.6/24.7 for patients with a lower ratio.CONCLUSION: T-lymphocyte subpopulations might be prognostic in resectable PDAC but need standardization and verification by further studies.

AB - BACKGROUND: We studied the prognostic effect of CD3-, CD8- and CD103-positive T lymphocytes in a cohort of 165 patients with resected pancreatic ductal adenocarcinomas (PDACs) of the treatment group (adjuvant gemcitabine) and the untreated control group of the CONKO-001 study.METHODS: Immunohistochemical stainings on tissue microarrays (TMAs) against CD3, CD8 and CD103 were performed according to standard procedures.RESULTS: A high number of CD8-positive lymphocytes were significantly and independently associated with longer disease-free survival (DFS) and overall survival (OS) in the overall study population. Median DFS/OS were 7.4/18.1 months for patients with a low number of CD8-positive intratumoural lymphocytes (≤42 per 1 mm tissue core) and 12.7/25.2 months for patients with high numbers (>42 per 1-mm tissue core; p = 0.008/0.020; HR 0.62/0.65). The ratio of intraepithelial to total CD103-positive lymphocytes, but not total numbers of CD103-positive lymphocytes or CD103-positive intraepithelial lymphocytes, was associated with significantly improved DFS and OS in the overall study population (p = 0.022/0.009). Median DFS/OS was 5.9/15.7 for patients with a ratio of intraepithelial to total CD103-positive intratumoural lymphocytes higher than 0.3 and 11.6/24.7 for patients with a lower ratio.CONCLUSION: T-lymphocyte subpopulations might be prognostic in resectable PDAC but need standardization and verification by further studies.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Antimetabolites, Antineoplastic/therapeutic use

KW - CD3 Complex/metabolism

KW - CD8-Positive T-Lymphocytes/immunology

KW - Carcinoma, Pancreatic Ductal/immunology

KW - Deoxycytidine/analogs & derivatives

KW - Disease-Free Survival

KW - Female

KW - Humans

KW - Integrin beta4/analysis

KW - Lymphocytes, Tumor-Infiltrating/immunology

KW - Male

KW - Middle Aged

KW - Pancreatic Neoplasms/immunology

KW - Prognosis

KW - T-Lymphocytes, Cytotoxic/immunology

U2 - 10.1016/j.ejca.2017.06.016

DO - 10.1016/j.ejca.2017.06.016

M3 - SCORING: Journal article

C2 - 28772128

VL - 83

SP - 290

EP - 301

JO - EUR J CANCER

JF - EUR J CANCER

SN - 0959-8049

ER -